2022
PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH
Tempest P, Lin Y, Tai C, Ono M, Russell D, Sandiego C, Carroll V, Gunn R, Margolin R, Higuchi M, Jang M. PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063028.Peer-Reviewed Original ResearchAD subjectsMulticenter phase 2 clinical trialAlzheimer's diseasePhase 2 clinical trialTau PET tracersPET imaging agentSimilar brain regionsCortical uptakeTest-retest studyCN subjectsClinical trialsNormal subjectsTau tracersBrain regionsSUV valuesDiverse tauopathiesPET tracersSame rank orderSUVR imagesImaging agentImaging profileDiseasePROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH
Tempest P, Lin Y, Tai C, Ono M, Russell D, Sandiego C, Gunn R, Carroll V, Margolin R, Kao T, Higuchi M, Jang M. PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063025.Peer-Reviewed Original ResearchAD subjectsMulticenter phase 2 clinical trialAlzheimer's diseasePhase 2 clinical trialTau PET tracersPET imaging agentSimilar brain regionsCortical uptakeTest-retest studyCN subjectsClinical trialsNormal subjectsTau tracersBrain regionsSUV valuesDiverse tauopathiesPET tracersSame rank orderSUVR imagesImaging agentImaging profileDisease
2021
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers
Kielbasa W, Shcherbinin S, Goldsmith P, Phipps K, Biglan K, Mancini M, Russell D, Constantinescu C, Gunn R, Nuthall H, Mergott D, Lowe S, Collins E. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.057774.Peer-Reviewed Original ResearchHealthy volunteersEnzyme occupancyPET scansSingle doseMultiple-dose clinical studiesPost-dose intervalPositron emission tomography radioligandBaseline PET scanLonger clinical trialsTarget occupancyTau-related diseasesMultiple dosesMultiple dosingClinical trialsPlasma pharmacokineticsClinical studiesEfficacy trialsSD studiesDose selectionTomography radioligandEnzyme inhibitorsPotential treatmentAlzheimer's diseasePET studiesTarget engagement
2014
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit
Beal M, Oakes D, Shoulson I, Henchcliffe C, Galpern W, Haas R, Juncos J, Nutt J, Voss T, Ravina B, Shults C, Helles K, Snively V, Lew M, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters C, Figueroa A, Arkun A, Brodsky M, Ondo W, Hunter C, Jimenez-Shahed J, Palao A, Miyasaki J, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell D, Cotto C, Friedman J, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford D, Grimes D, Cote D, Conway J, Siderowf A, Evatt M, Sommerfeld B, Lieberman A, Okun M, Rodriguez R, Merritt S, Swartz C, Martin W, King P, Stover N, Guthrie S, Watts R, Ahmed A, Fernandez H, Winters A, Mari Z, Dawson T, Dunlop B, Feigin A, Shannon B, Nirenberg M, Ogg M, Ellias S, Thomas C, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser R, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi K, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson V, Markind S, Pelikan M, Perlmutter J, Hartlein J, Molho E, Evans S, Adler C, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey M, Hermanowicz N, Niswonger S, Shill H, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer K, Bergholte J, Propsom C, Stacy M, Field J, Mihaila D, Chilton M, Uc E, Sieren J, Simon D, Kraics L, Silver A, Boyd J, Hamill R, Ingvoldstad C, Young J, Thomas K, Kostyk S, Wojcieszek J, Pfeiffer R, Panisset M, Beland M, Reich S, Cines M, Zappala N, Rivest J, Zweig R, Lumina L, Hilliard C, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang U, Young J, Rao J, Cook M, Severt L, Boyar K. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurology 2014, 71: 543-552. PMID: 24664227, DOI: 10.1001/jamaneurol.2014.131.Peer-Reviewed Original ResearchConceptsTotal UPDRS scoresUPDRS scoresCoenzyme Q10PD medicationsFinal visitClinical benefitClinical trialsEarly-phase human studiesPrevious phase II studyDouble-blind clinical trialMini-Mental State Examination scoreParticipants 30 yearsPhase III randomizedPrespecified futility criterionDrug-induced parkinsonismPhase II studyActive treatment groupIU/dEarly Parkinson's diseaseHistory of strokePossible clinical benefitPrimary outcome measureState Examination scoreParkinson's disease modelDiagnosis of PD